Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March [Yahoo! Finance]
Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN)
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study. In addition, all money-losing biotechs sold off hard along with the broader market, as lower equity valuations could make it harder for these companies to raise capital to fund their research. Finally, the resignation of a key Federal Food and Drug Administration (FDA) regulator toward the end of the month cast a pall over the FDA approval process under the tenure of new Secretary of Health and Human Services, Robert F. Kennedy Jr. March was clearly a bad month for any stock deemed "risky" by investors. Profound uncertainty over tariffs and the economic outlook likely spurred factor-oriented investment funds to sell stocks with certain "high-risk" characteristics such as a high beta, which describ
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Pharmaceutical Holding Company Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]Yahoo! Finance
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology CongressPR Newswire
- Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]Yahoo! Finance
- Biohaven (NYSE:BHVN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
BHVN
Earnings
- 11/10/25 - Beat
BHVN
Sec Filings
- 11/18/25 - Form 4
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- BHVN's page on the SEC website